Overview. Complex Cases in PCI: Tailoring Antiplatelet Therapy to Improve Outcomes.

Slides:

Advertisements

Similar presentations

Invasive Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATelet Inhibition and patient Outcomes trial Outcomes in.

Advertisements

J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig. Abciximab in Patients.

Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents Tim Kinnaird, University Hospital Wales, Cardiff and Vale NHS Trust.

Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.

1 Update on antiplatelet and anticoagulant drugs: sticky stuff KFJ Ng May 2011.

Robert F. Storey Senior Lecturer and Honorary Consultant in Cardiology, University of Sheffield, Sheffield, UK Stent thrombosis Future directions.

Evolution of pharmaceutical antithrombotic therapy in CVD Dr Rob Butler Dept of Cardiology University Hospital of North Staffordshire Drug It!

Meta Analysis of Primary PCI trials Andreas Baumbach*, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran,

The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.

Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.

Adjunctive Antithrombotic for PCI Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville.

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.

Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock – a.

Pharmacotherapy Update for STEMI: What Is New?

Heparin Should be the First-line Therapy for Patients with ACS/AMI

When should we start a P2Y12 inhibitor in patients with an acute coronary syndrome? G. Montalescot Dr. Montalescot reports research Grants to the Institution.

Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.

Randomisation before planned PCI with DES (n=2500)

Should We Preload STEMI Patients with Antiplatelet Therapy?

Antiplatelet Therapy For STEMI: The Case for Cangrelor

Ischaemic Heart Disease Acute Coronary Syndrome

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Cardiogenic Shock.

The Clinical Enigma of Cardiogenic Shock

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Emerging Data on ACS Management From ACC

The Nurse View.

PAD Patients vs Post-ACS Patients:

Figure 3 Metabolism pathway of antiplatelet agents

Glenn N. Levine et al. JACC 2016;68:

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.

Nat. Rev. Cardiol. doi: /nrcardio

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Tailoring Antiplatelet Therapy in PCI

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Nat. Rev. Cardiol. doi: /nrcardio

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Are We Closer to Personalized Medicine in MS?

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

A Hard Look at Cardiogenic Shock: IABP-SHOCK II Revisited

Improving Appropriate Access to PCSK9 Inhibitors

Section F: Clinical guidelines

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Nat. Rev. Cardiol. doi: /nrcardio

CV Risk Doesn't End in the Cath Lab

Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization A meta-analysis of randomized trials performed in the.

Factor Xa Inhibitors in PAD

Cancer-Associated Thrombosis

What oral antiplatelet therapy would you choose?

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization A meta-analysis of randomized trials performed in the.

Factor Xa Inhibitors in Coronary Artery Disease

Improving Adherence to Antiplatelet Therapy After an ACS Event

Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges

Roberta Rossini et al. JCIN 2018;11:

OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)

Tailoring Therapy in the Newly Diagnosed Patient With CLL

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

ESC Guideline on the Management of STEMI Recommendation for DAPT

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

Section C: Clinical trial update: Oral antiplatelet therapy

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Complex Cases in PCI: Tailoring Antiplatelet Therapy to Improve Outcomes

Overview

Case 1: Antiplatelet Strategy for High-Risk PCI of STEMI

P2Y12 Inhibitor Pretreatment Concerns

Pros and Cons of Upstream vs Downstream Use of P2Y12 Receptor Inhibitors

Novel Oral P2Y12 Effects in Patients With STEMI

Is Drug "Crushing" a Viable Pretreatment Strategy?

Other Pretreatment Strategies

Case 2: Antiplatelet Strategies for STEMI and Cardiogenic Shock

IV Antiplatelet Agents: Cangrelor vs GPIs

Expert Consensus Recommendations on Switching

Cangrelor Platelet Reactivity by Day

STEMI Without CS: Crushed Oral vs IV P2Y12 Inhibitors

Propensity-Matched Analysis Comparing Cangrelor Alone vs Clopidogrel Plus GPIs in the CHAMPION Trials

CHAMPION: Pooled Acquired Thrombocytopenia (TCP) 48-Hour Ischemic Outcomes, Stratified By Acquired TCP

Strategies for Patients With NSTEMI and UA

Strategies for Complex PCI

Cangrelor to Thienopyridine Transition

Cangrelor to Ticagrelor Transition

Team-Based Strategies

Abbreviations

Abbreviations (cont)